Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori

Table 2

H. pylori eradication rates of each group in PP and ITT analysis.

Population	Eradication by group (%)
	RMAB		RMMB		RACB
	(%)	95% CI	(%)	95% CI	(%)	95% CI
ITT	102/119 (85.7)	79.3~92.1	91/118 (77.1)	69.4~84.8	86/120 (71.7)	63.5~79.8	0.030
PP	102/114 (89.5)	83.8~95.2	91/108 (84.3)	77.3~91.2	86/112 (76.8)	68.8~84.7	0.036

, RMAB vs. RACB; , RMAB vs. RMMB; , RMMB vs. RACB. , RMAB vs. RACB; , RMAB vs. RMMB; , RMMB vs. RACB. RMAB group: rabeprazole plus minocycline, amoxicillin, and bismuth; RMMB group: rabeprazole plus minocycline, metronidazole, and bismuth; RACB group: rabeprazole plus amoxicillin, clarithromycin, and bismuth. ITT: intention-to-treatment; PP: per-protocol; CI: confidence interval.